Merck extends deal to see what else NGM's discovery engine can come up with
Once again, Merck is re-upping its collaboration with NGM Biopharmaceuticals, which former R&D chief Roger Perlmutter personally negotiated back in 2015. But not all compounds are making the cut, as the pharma says ‘no thank you’ to NGM’s slate of oncology candidates.
The extension, which now goes to March 2024, will focus on the development of medicines for retinal and cardiovascular and metabolic (CVM) diseases, including heart failure, the partners said on Thursday. They had announced back in March that they were renegotiating the terms of the agreement to “better address their respective evolving priorities.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.